Evidence map›Paper›PMID 38690167›Full record

ArticleFrontiers in oncology2024

Case report: Acquired resistance to crizotinib from a MET Y1230H mutation in a patient with non-small cell lung cancer and

Su-Su Dong, Wen Dong, Ya-Fen Tan, Qiang Xiao, Tian-Li Wang

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Su-Su Dong *Department of Respiratory Medicine, Changde Hospital, Xiangya School of Medicine, Central South University (the First People's Hospital of Changde City), Changde, Hunan, China.
Wen Dong *Department of Oncology, Changde Hospital, Xiangya School of Medicine, Central South University (the First People's Hospital of Changde City), Changde, Hunan, China.
Ya-Fen TanDepartment of Respiratory Medicine, Changde Hospital, Xiangya School of Medicine, Central South University (the First People's Hospital of Changde City), Changde, Hunan, China.
Qiang XiaoDepartment of Respiratory Medicine, Changde Hospital, Xiangya School of Medicine, Central South University (the First People's Hospital of Changde City), Changde, Hunan, China.
Tian-Li WangDepartment of Respiratory Medicine, Changde Hospital, Xiangya School of Medicine, Central South University (the First People's Hospital of Changde City), Changde, Hunan, China.
The First People's Hospital of Changde · CNCentral South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The c-met proto-oncogene ( Case description: The patient initially exhibited partial response to first-line crizotinib treatment, albeit for a short duration and with limited efficacy. Subsequent disease progression revealed the emergence of a secondary Conclusion: The reporting of this case is imperative for informing clinical practice, given the uncommon occurrence of NSCLC with

Indexed as

acquired resistancecrizotinibgene mutationsMET fusionnon-small cell lung cancer

Identifiers

PMID38690167
PMCPMC11059057
OpenAlexW4394850128

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.